HYPERCALCEMIA TREATMENT MARKET ANALYSIS

Hypercalcemia is a condition in which the blood calcium level is abnormally high. Excess calcium in the blood can cause kidney stones, weaken the bones, and disrupt the functioning of brain and heart. Overactive parathyroid glands are the most common cause of hypercalcemia. These small glands are located near the thyroid gland in the neck. Cancer, certain drugs, some other medical diseases, and taking too much calcium and vitamin D supplements are some of the possible causes of hypercalcemia.

The global hypercalcemia treatment market is estimated to be valued at US$ 3,478.6 million in 2021, and is expected to exhibit a CAGR of 8.1% during the forecast period (2021-2028).

Figure 1. Global Hypercalcemia Treatment Market Share (%) in Terms of Value, by Indication, 2021

To learn more about this report, request sample copy

Increasing prevalence of chronic diseases is expected to drive the market growth during the forecast period.

The increasing prevalence of chronic diseases such as cancer is expected to increase the incidence of hypercalcemia, in turn driving the global hypercalcemia treatment market growth in the forecast period. As hypercalcemia may be caused by cancer and other conditions, its increasing prevalence is expected to drive the market growth. For instance, according to the Centers for Disease Control and Prevention, in 2018, there were 1,708,921 new cancer cases reported in the U.S. and 599,265 people died from cancer.

Figure 2. Global Hypercalcemia Treatment Market Share (%), by Distribution Channel, 2021

To learn more about this report, request sample copy

Increasing research and development activities by the key players is expected to drive the market growth during the forecast period.

The increasing research and development activities related to hypercalcemia treatment by the key players operating in the market is expected to fuel growth of the global hypercalcemia treatment market over the forecast period. For instance, in April, 2019, Kyowa Hakko Kirin Co., Ltd., a Japanese pharmaceutical company, announced that it had submitted a supplemental application to Japan's Ministry of Health, Labor, and Welfare (MHLW) for KHK7580 (evocalcet) for treating hypercalcemia in patients with primary hyperparathyroidism or parathyroid carcinoma. Moreover, this application is based on the preliminary (24-week) results of a phase III study evaluating the efficacy of KHK7580.

Global Hypercalcemia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The spread of the coronavirus has had a far-reaching impact on all aspects of life around the world, including drug clinical trials. Clinical trials are the most important and necessary part of drug research and development; therefore, unlike ordinary patient diagnosis and treatment, clinical trial implementation must strictly adhere to the trial protocol, ethics, and relevant regulations in addition to the common diagnosis and treatment process. For instance, according to the article published in the Nepal Journal of Epidemiology, in September 2020, Medidata technology and solutions, a global platform that supports clinical trials, conducted an electronic survey of 9,952 trial investigator site personnel. Moreover, according to the survey results, the ability to conduct ongoing clinical trials during the COVID-19 pandemic impacted 69% of respondents, while 78% stated that this situation impacted the initiation of new trials.

Furthermore, the primary concerns raised by these survey respondents that limited their ability were subject enrollment, patient recruitment, financial losses due to study cancellation, and financial implications from delayed endpoints. Overall, these issues negatively impacted the clinical trial and drug development processes worldwide. Hence, the impact of COVID-19 is expected to hamper growth of the global hypercalcemia treatment market over the forecast period.

Global Hypercalcemia Treatment Market: Restraint

The major factor that hinder growth of the global hypercalcemia treatment market include side effects of drugs for hypercalcemia. The increasing side effects of the drugs prescribed for hyperparathyroidism which is the main cause of hypercalcemia, is expected to hamper growth of the global hypercalcemia treatment market during the forecast period. For instance, some of the common side effects of Cinacalcet, which belongs to the drug class calcimimetics include diarrhea, nausea, vomiting, myalgia (muscle pain), stomach upset, weakness, and abdominal pain.

Key Players

Major players operating in the global hypercalcemia treatment market include Bayer AG, Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Amgen Inc., Viatris Inc. (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Pvt. Ltd., Apotex Inc., Crinetics Pharmaceuticals, Inc., Alkem Labs, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals, and Slate Run Pharmaceuticals.